Dear E-druggers,
Blister packs are in some situation, such as in the China project (see
Lancet, vol 347, N 8998, 10 Feb 1996, p. 358-362) a useful complement
of the full DOTS strategy. None of the single components of the
strategy (which are political committments, good case finding methods,
standardised regimens provided by direct administration during at
least the initial phase, regular drug supply and a standard
information system allowing cohort analysis of treatment outcomes) has
significant impact on improving programme effectiveness. We at GTB
fully favour the use of fixed dose combinations products (at least R
plus H) as recommended by WHO and IUATLD in any country, both in the
government and private sectors. Blister packs are not a substitute of
FDC nor of the directly observed treatment (DOT).
I hope to have replied to your question.
Sincerely
Dr. Spinaci
Chief WHO/NPS/GTB
E-mail: spinacis@who.ch
--
Send mail for the `E-Drug' conference to `e-drug@usa.healthnet.org'.
Mail administrative requests to `majordomo@usa.healthnet.org'.
For additional assistance, send mail to: `owner-e-drug@usa.healthnet.org'.